Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vor Biopharma Inc (VOR)

Vor Biopharma Inc (VOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China GlobeNewswire - Mon Jun 8, 7:31AM CDT

First regulatory approval for Sjögren’s disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating...

VOR : 14.48 (-2.49%)
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China GlobeNewswire - Mon Jun 8, 7:30AM CDT

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)  Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published...

VOR : 14.48 (-2.49%)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Jun 1, 4:00PM CDT

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026,...

VOR : 14.48 (-2.49%)
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference GlobeNewswire - Thu May 28, 7:30AM CDT

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate...

VOR : 14.48 (-2.49%)
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine GlobeNewswire - Thu May 14, 7:30AM CDT

Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment  Results further support the potential for telitacicept...

VOR : 14.48 (-2.49%)
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire - Wed May 13, 7:30AM CDT

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of...

VOR : 14.48 (-2.49%)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon May 4, 3:30PM CDT

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Compensation...

VOR : 14.48 (-2.49%)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Apr 1, 4:00PM CDT

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the...

VOR : 14.48 (-2.49%)
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update GlobeNewswire - Mon Mar 30, 7:01AM CDT

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports telitacicept...

VOR : 14.48 (-2.49%)
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease GlobeNewswire - Mon Mar 30, 7:00AM CDT

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient...

VOR : 14.48 (-2.49%)

Barchart Exclusives

If You Crave Dividends, This Tasty Dividend Stock Is a Buy at New 52-Week Lows Barchart - Wed Jun 24, 6:30PM CDT
Domino's Pizza stock fell to a 52-week low on June 23. With a dividend yield of 2.7% and a reasonable valuation, DPZ stock is a decent buy for income-seeking investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.